Elanco Animal Health Incorporated (ELAN)

Market Cap	7.24B
Revenue (ttm)	4.49B
Net Income (ttm)	-1.26B
Shares Out	494.33M
EPS (ttm)	-2.55
PE Ratio	n/a
Forward PE	16.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,644,271
Open	14.31
Previous Close	14.29
Day's Range	14.26 - 14.95
52-Week Range	8.52 - 18.80
Beta	1.41
Analysts	Buy
Price Target	17.50 (+19.45%)
Earnings Date	Nov 5, 2024

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticid...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 20, 2018
• Employees: 9,800
• Stock Exchange: NYSE
• Ticker Symbol: ELAN
• Website: https://www.elanco.com

Financial Performance

In 2023, Elanco Animal Health's revenue was $4.42 billion, an increase of 0.14% compared to the previous year's $4.41 billion. Losses were -$1.23 billion, 1478.2% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 19.45% from the latest price.

Price Target

$17.5

(19.45% upside)

Analyst Consensus: Buy